359
Views
23
CrossRef citations to date
0
Altmetric
Inflammatory Bowel Disease

Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: A Danish single center experience

, &
Pages 1457-1463 | Received 02 May 2010, Accepted 05 Jul 2010, Published online: 11 Aug 2010

References

  • Jarnerot G, Rolny P, Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 1985;89:1005–13.
  • Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, Jewell DP. Predicting outcome in severe ulcerative colitis. Gut 1996;38:905–10.
  • Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974;1:1067–70.
  • Arts J, D'Haens G, Zeegers M, Van Assche G, Hiele M, D'Hoore A, Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004;10:73–8.
  • Garcia-Lopez S, Gomollon-Garcia F, Perez-Gisbert J. Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. Gastroenterol Hepatol 2005;28:607–14.
  • Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805–11.
  • Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.
  • Gustavsson A, Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Colectomy after rescue therapy in intravenous-steroid resistant acute ulcerative colitis: a 3-year follow-up study of the swedish-danish infliximab/placebo trial. Abstract, UEGW Vienna 2008.
  • Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009;137:1250–60.
  • Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative Colitis. Gut 2010;59:49–54.
  • Aratari A, Papi C, Clemente V, Moretti A, Luchetti R, Koch M, Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis 2008;40:821–6.
  • Cury DB, Cury Mde S, Elias GV, Mizsputen SJ. Infliximab to treat severe ulcerative colitis. World J Gastroenterol 2009;15:1771–3.
  • Manosa M, Lopez SR, Garcia-Planella E, Bastida G, Hinojosa J, Gonzalez-Lama Y, Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis. Digestion 2009;80:30–5.
  • Willert RP, Lawrance IC. Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. World J Gastroenterol 2008;14:2544–9.
  • Gonzalez-Lama Y, Fernandez-Blanco I, Lopez-SanRoman A, Taxonera C, Casis B, Tabernero S, Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology 2008;55:1609–14.
  • Kohn A, Daperno M, Armuzzi A, Cappello M, Biancone L, Orlando A, Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007;26:747–56.
  • Russo EA, Harris AW, Campbell S, Lindsay J, Hart A, Arebi N, Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Aliment Pharmacol Ther 2009;29:308–14.
  • Bressler B, Law JK, Nahdi Al, Sheraisher N, Atkinson K, Byrne MF, The use of infliximab for treatment of hospitalized patients with acute severe ulcerative coitis. Can J Gastroenterol 2008;22:937–40.
  • Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749–53.
  • Ferrante M. Long-term outcome after infliximab for refractory ulcerative colitis. J Chron's Colitis 2008;2:219–23.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.